Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma

Our plain-English summary of Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma, by H. Hu, L. Li, W. Bian, et al (Discover Oncology, 2026).

The study

• Authors: H. Hu, L. Li, W. Bian, X. Wu
• Journal: Discover Oncology
• Published: 2026;17(1)
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive and molecularly heterogeneous malignancy with poor prognosis. Here, we performed an integrative multi-omic analysis combining bulk transcriptomics, copy number variation profiling, and single-cell RNA sequencing to systematically characterize MPM heterogeneity. Using non-negative matrix factorization, we identified three robust molecular subtypes (S-I, S-II, and S-III) with distinct transcriptional programs, genomic alterations, and tumor microenvironment compositions. Subtype S-I exhibited immune-inflamed signatures with abundant cytotoxic T cells and activated dendritic cells, suggesting potential responsiveness to immunotherapy. S-II was characterized by metabolic reprogramming and mTORC1 pathway activation, whereas S-III displayed stromal enrichment, extracellular matrix remodeling, and suppressed apoptotic signaling. Single-cell analysis revealed subtype-specific distributions of malignant and stromal cell subsets, corroborating bulk-level observations and highlighting intratumoral heterogeneity. Collectively, these findings refine the molecular classification of MPM, uncover subtype-specific regulatory programs, and identify potential therapeutic vulnerabilities, providing a framework for precision medicine strategies in this challenging malignancy.

In plain English

This was a computer-based analysis of previously published tumor data from people with malignant pleural mesothelioma. It did not study asbestos exposure. The authors sorted gene-activity profiles from 87 tumor samples in The Cancer Genome Atlas (TCGA) into three molecular subtypes: S-I (16 patients), S-II (42) and S-III (29). They compared these with a second dataset (GSE29211) and with single-cell data from an earlier study. S-I tumors showed signs of high immune activity. S-II tumors mainly carried gains in gene copies and had more active mTORC1-related genes. S-III tumors carried widespread gene-copy losses, more fibroblasts, lower activity of pro-apoptotic genes, more biphasic tumors and more advanced T and N stages. Patients in S-III had significantly worse overall survival than those in S-I and S-II in both datasets, but the text gives no survival figures. Based on gene activity alone, the authors suggested S-I may respond better to immune checkpoint inhibitors, and S-II and S-III to targeted drugs. No treatments were tested. The authors noted a moderate sample size, few sarcomatoid samples, data from a single time point, and the need for laboratory confirmation.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Computational (bioinformatic) analysis of existing public gene-expression, copy-number and single-cell RNA sequencing datasets; no new patients were recruited
• Who was studied: 87 primary malignant pleural mesothelioma tumor samples from the TCGA cohort, with the GSE29211 cohort used for comparison and single-cell data taken from a previous study (GSE190597); the text does not state how many samples were in GSE29211 or the single-cell data
• Exposure: Not studied. Asbestos is mentioned only in the introduction as background, citing other work; the study analyzed tumor gene data, not exposure
• Main results:
  • The TCGA tumors were divided into three molecular subtypes: 16 in S-I, 42 in S-II and 29 in S-III
  • Patients in subtype S-III had significantly worse overall survival than those in S-I and S-II, in both cohorts (no survival numbers given in the text)
  • Subtype S-III contained more biphasic tumors, consistently in the TCGA and GSE29211 cohorts
  • Subtype S-III had a higher proportion of patients with advanced T-stage and N-stage than S-I and S-II
  • Subtype S-I showed significant enrichment of immune-related pathways and of multiple pro-inflammatory immune cells
  • Copy-number changes were mostly gains (amplifications) in S-II and widespread losses (deletions) in S-III
  • mTORC1-related genes were upregulated in S-II, and pro-apoptotic genes were downregulated in S-III
  • S-III showed a stroma-rich pattern with significantly higher estimated proportions of fibroblasts and endothelial cells
  • In single-cell data, inflammatory and metabolic cancer cell subsets were enriched in S-I, epithelioid and stressed subsets in S-II, and mesothelium-like, mesenchymal and sarcomatoid subsets in S-III
  • From expression levels of drug-target genes only (no drugs were tested), the authors suggested S-II and S-III may be more responsive to targeted therapies and S-I to immune checkpoint inhibitors
• The authors' conclusion: The authors concluded that their three-subtype model of malignant pleural mesothelioma gives insight into tumor heterogeneity and identifies potential biomarkers and therapeutic targets
• Limitations the authors state:
  • Moderate sample size may limit the ability to capture rare subtypes or account for differences between cohorts
  • The data come from a single time point, so changes in subtype over time or during treatment could not be studied
  • Suggested links between copy-number changes and pathway activity need laboratory (functional) confirmation
  • Few sarcomatoid mesothelioma samples were available in the cohorts

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Prognosis, Tumor Microenvironment, Immunotherapy.

Related studies

• Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy — H. Li, K. Zhou, et al. (2026)
• Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer — D. Pandit, A. Dhillon, et al. (2026)
• Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma — C. Meiller, F. Montagne, et al. (2021)
• Evidence Based on an Integrative Analysis of Multi-Omics Data on METTL7A as a Molecular Marker in Pan-Cancer — Z. Liu, Y. Chen, et al. (2023)
• A comprehensive investigation on pan-cancer impacts of constitutive centromere associated network gene family by integrating multi-omics data: A CONSORT-compliant article — H. Su, Y. Fan, et al. (2022)
• Exploring the Impact of DNA Methylation on Gene Expression in CRC: A Computational Approach for Identifying Epigenetically Regulated Genes in Multi-Omic Datasets — A.S. Blindu, S. Berardelli, et al. (2026)

Browse more research in Discover Oncology, or return to medical research.